Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03789110
Title NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Dana-Farber Cancer Institute Boston Massachusetts 02215 United States Details
University of Pittsburgh Medical Center Pittsburgh Pennsylvania 15213 United States Details
University of Texas Southwestern Medical Center Dallas Texas 75390 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field